Dural Graft Market

Dural Graft Market Outlook (2023 to 2033)

The Global Market for Dural Graft stands at US$ 750.5 Million in 2022, with the global market expected to grow at a CAGR of 5.7% to reach a valuation of around US$ 1.38 Billion by the end of 2033.

As assessed by Persistence Market Research, Traumatic Brain and Spine Injury held a market share of around 51.4% in the global market, in 2022. The global dural graft market holds nearly 11% revenue share of the global soft tissue repair market valued at US$ 6.16 Billion in 2022.

Sales Analysis of Market from 2013 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 5.1% in the last 9 years from 2013 to 2022.

The global market is likely to show high growth over the coming years at a CAGR of 5.7% and reach a global market size of 1.38 Billion by 2033.

The repair of outermost layer that protects the brain and spinal cord, is essentially what is meant by "dural repair." Adults undergoing this procedure will have their adult dura mater repaired using synthetic or biological mesh.

The most frequent problems, including cerebrospinal fluid (CSF) leakage, illnesses, hypertensive pneumocephalus, pseudomeningocele, and others that prolong hospital stays, require the watertight closure of the dura mater.

The removal of bigger lesions leaves behind daunting, intricate defects in the dura, bone, and soft tissue that must be fixed. As a result, different kinds of substance have been assessed to find the best dural replacement method. Autologous tissues (pericardium, fascia lata, fat, muscle) or synthetic dural substitutes may be used as dural substitutes.

Due to an increase in cranial and spinal duraplasties caused by neurosurgical illnesses, as well as quick technological improvements in dural graft products, the need for dural graft is anticipated to increase dramatically globally.

Further, a growing need for CNS dural repair, substantial clinical research, and an expanding global neurosurgical workforce are driving use of dural transplant products.

How Can the Global Market Grow?

“Rising Incidence of Neurological Disorders and Increasing Awareness about Neurological Conditions”

An important and growing global health issue, neurological illnesses make up a sizeable component of the global disease burden.

• According to a study published in Frontiers (2022) on the global, regional, and national burden and associated risk factors of neurological illnesses, there were 349 million DALYs and over 10 million fatalities worldwide in 2019 as a result of neurological disorders. Stroke was the leading cause of DALYs among the 18 neurological illnesses.

The Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022-2031 was adopted on May 27 2022 by the 75th World Health Assembly (IGAP). By establishing the IGAP, WHO has vowed to give brain health top priority over the following ten years. Given that neurological illnesses are the primary cause of disability and the second greatest cause of death worldwide, this action is both overdue and essential.

As a result, the rising neurological disorders as well as awareness regarding neurological illnesses are uplifting the dural graft market.

“Increased Preference for Xerographic Dural Grafts and Advanced Dural Graft Material”

Due to superior patient compatibility and fewer postoperative problems than synthetic dural grafts, numerous neurosurgeons favour natural and biological source dural grafts. It is anticipated that neurosurgeons will continue to accept xerographic dural transplant.

Next-generation synthetic dural grafts are projected to have new opportunities because to advancements in material nanotechnology and scientific principles. The bio-absorbable, nanostructured synthetic graft is anticipated to be preferred by neurosurgeons because to its affordability and patient comfort.

Can the Market Growth Be Affected in Any Way?

“Lack of Skilled Neurosurgeon Workers”

There has been a high demand for neurosurgeons who deals into surgeries pertaining to usage of dural graft. However, lack of neurosurgical care providers leads to more than 5 million neurosurgical cases to go untreated every year.

• According to WHO estimation, there are just 16-trained personnel for every 10,000 people in the population, compared to 29 for the entire health staff in 2019.
• The educated health workforce in India somehow does not meet the minimum standard of 22.8 skilled workers per 10,000 people set by the World Health Organization, according to a study that was published in the BMJ online journal (2019).

Similarly, overall high cost associated with neurosurgeries from hospitalization to post-operative care is expected to slow down the dural graft market.

Country–wise Insights

Why is the United States Market Booming?

“Increased TBI Related Deaths”

The United States accounted for around 28.9% market share in the global market in 2022.

Compared to all other age groups in the United States, older persons are more likely to require hospitalisation and pass away from a TBI. However, because TBI symptoms coincide with those of other medical illnesses that are frequent in older persons, such as dementia, TBIs may be ignored or incorrectly diagnosed in older adults.

• The Centers for Disease Control and Prevention estimated that over 64,000 Americans would die in 2020 as a result of TBI. 3 That equates to around 176 fatalities from TBI per day.

As a result, more Americans are being diagnosed with these medical issues, which is driving up demand.

Will the China Be a Lucrative Market for Dural Graft?

“Rising Incidences of Brain and Central Nervous System Tumours”

The China market held around 10.7% market share of the global market in 2022.

Brain and CNS tumour pose a substantial hazard to the population's health in China.

• According to the World Health Organization (WHO), China experienced a significant illness burden in 2020 with 79,575 clinically diagnosed brain and CNS tumour patients and 65,204 fatalities.

Because of this, neurological procedures are becoming more and more popular in China, which is driving the market.

Category–wise Insights

Which Product Is Rising Within the Market?

“High Success Rate of Xenogeneic Dural Graft”

Xenogeneic dural graft segment held around 33.4% share of the total market in 2022.

The clinical results of duraplasty employing xenogeneic grafts have been similar and successful. The complicated study of the fascia, pericardium, and dura mater xenogeneic grafts used for duraplasty in neurosurgery during the past 20 years revealed them to be extremely good, with a success rate of 96.9%.

Which Application is Driving Demand within the Global Market?

“Growing Cases of Traumatic Brain Injuries”

The Traumatic Brain and Spine segment held around 51.4% share of the total market in 2022.

There is a significant public health burden associated with traumatic brain injury (TBI), which has the highest prevalence of all prevalent neurological illnesses. TBI is becoming more and more well-documented as a chronic disease with long-term effects, including an elevated risk of late-onset neurodegeneration, in addition to an acute condition. The age group between 65 and 74 years old has the highest rate of TBI hospital admissions, followed by children and teenagers. TBI rates among older adults are rising and, in certain nations, outpace population growth.

Consequently, the growing geriatric population in the world to demand for traumatic brain and spine surgeries.

Which Material Type is adopted within the Global Market?

“Extensive Usage, Accessibility, Customization Option, and Hemostatic Nature of Autologous pericardium”

Autologous Pericardium held around 33.3% share of the total market in 2022.

Arterial or venous auto grafts, or the patient's own blood vessels, including the internal mammary artery, the radial artery, or the great saphenous vein, are the most common types of autologous blood vessel replacements. Gold standard materials, with the finest long-term patency, are autologous vessels. In pediatric cardiac surgery, autologous pericardium is one of the most often used materials for reconstruction due to its low immunogenicity and low propensity to calcify.

Which End User is Usually Accepted?

“Access for Emergency Treatment with the Professional Workers”

Hospitals held around 57.2% share of the total market in 2022.

Hospitals use dural grafts for a variety of therapeutic purposes. After an accident or injury, it is frequently required in the emergency room to replace a patient's injured or missing dura mater with a graft of fresh tissue that quickly protects the unprotected brain and nerve structures. Dural Graft is also particularly beneficial in endoscopic treatments carried out in Ambulatory Surgical Centers (ASCs), where doctors try to reach parts of the body without making significant incisions that would have allowed them to do so directly.

Competition Landscape

The businesses' main priorities are to increase production volume, improve their line neurological surgeries, introduce advanced features, and introduce new products. For accelerated and improved treatments, several businesses are going for tie ups with hospital vendors and physicians.

Some key instances of development include:

• Baxter International Inc’s bone graft substitute named Altapore Shape Bioactive Bone Graft received FDA approval on July 2020
• B. Braun Medical Inc. (B. Braun) collaborated with Association for Vascular Access (AVA) and launched the Fundamentals of Peripheral IV Access eLearning Program on Sept 29 2022. This is an extensive eLearning curriculum concentrating on fundamental, intermediate, and advanced ideas in vascular access and patient outcomes.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the Dural Graft market, which are available in the full report.

Companies Covered in Dural Graft Market

• Cook Medical
• Intefra Lifesciences Corporation
• B Braun
• Cousin Biotech
• Natus Medical Incorporated
• Tissuemed Ltd
• Vostra Gmbh
• Stryker Corporation
• Medtronic Plc
• Johnson & Johnson
• Baxter International Inc